Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)
Background No treatment demonstrated to improve survival in patients with recurrent glioblastoma (rGB) in a randomized trial. Combining axitinib with the programmed cell death ligand 1 blocking monoclonal antibody avelumab may result in synergistic activity against rGB.Methods Adult patients with rG...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2020-10-01
|
| Serier: | Journal for ImmunoTherapy of Cancer |
| Online adgang: | https://jitc.bmj.com/content/8/2/e001146.full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|